Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents

被引:9
作者
Mancuso, M. E. [1 ]
Chantarangkul, V. [1 ]
Clerici, M. [1 ]
Fasulo, M. R. [1 ]
Padovan, L. [1 ]
Scalambrino, E. [1 ]
Peyvandi, F. [1 ,2 ]
Tripodi, A. [1 ,3 ]
Santagostino, E. [1 ]
机构
[1] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Via Pace 9, I-20122 Milan, Italy
[2] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy
[3] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
关键词
endogenous thrombin potential; haemophilia; inhibitors; orthopaedic surgery; Thrombin generation; RECOMBINANT FACTOR VIIA; PROTHROMBIN COMPLEX CONCENTRATE; HEMOPHILIA-A PATIENTS; ACTIVATED FACTOR-VII; SURGICAL INTERVENTIONS; SEQUENTIAL THERAPY; ASSAY; EXPERIENCE; INFUSION; FEIBA(R);
D O I
10.1111/hae.12939
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: In the presence of high-titre inhibitors, haemostatic bypassing agents are used to control bleeding and perform surgery. In this setting, no specific laboratory test is yet available to guide drug choice, monitor treatment efficacy and predict the risk of bleeding. Aim: The aims of this study, carried out in patients candidate to orthopaedic surgery, were to assess the dose-dependent increase in thrombin generation (TG) after infusion of bypassing agents and to evaluate whether or not a correlation existed between the haemostatic efficacy of bypassing therapies and perioperative TG values. Methods and Results: TG was measured in 16 inhibitor patients, 10 of whom underwent 11 major orthopaedic procedures. In the non-bleeding state, TG significantly improved 30 min after whichever dose (P < 0.01), with no dose-response relationship when values obtained after different rFVIIa doses were compared. TG significantly improved 30 min after the preoperative bolus (P < 0.05), while during the postoperative period TG values measured before and after dosing did not differ. Moreover, postoperative TG values were similar or even more impaired (P = 0.05) than those measured before preoperative dosing. No difference was found by comparing procedures with and without bleeding complications and yet no bleeding occurred in spite of persistently low TG values in one-third of procedures. Conclusion: This study fails to support a definite role for the TG assay as a reliable laboratory tool to monitor the haemostatic efficacy of bypassing therapies and as a predictor of the risk of bleeding in inhibitor patients using these agents during orthopaedic surgery.
引用
收藏
页码:E292 / E300
页数:9
相关论文
共 34 条
[1]   Feasibility of Using Thrombin Generation Assay (TGA) for Monitoring Bypassing Agent Therapy in Patients With Hemophilia Having Inhibitors [J].
Ay, Yilmaz ;
Balkan, Can ;
Karapinar, Deniz Yilmaz ;
Akin, Mehmet ;
Bilenoglu, Basri ;
Kavakli, Kaan .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2013, 19 (04) :389-394
[2]   Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors [J].
Berntorp, E. .
HAEMOPHILIA, 2009, 15 (01) :3-10
[3]  
Chantarangkul V, 2003, HAEMATOLOGICA, V88, P547
[4]   Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision [J].
Dargaud, Y ;
Lienhart, A ;
Meunier, S ;
Hequet, O ;
Chavanne, H ;
Chamouard, V ;
Marin, S ;
Negrier, C .
HAEMOPHILIA, 2005, 11 (05) :552-558
[5]   Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII [J].
Dargaud, Yesim ;
Bordet, Jean-Claude ;
Lienhart, Anne ;
Negrier, Claude .
SEMINARS IN HEMATOLOGY, 2008, 45 (02) :S72-S73
[6]   Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery [J].
Dargaud, Yesim ;
Lienhart, Anne ;
Negrier, Claude .
BLOOD, 2010, 116 (25) :5734-5737
[7]  
de Bosch NB, 2002, THROMB HAEMOSTASIS, V88, P253
[8]   Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa [J].
Eichinger, S. ;
Lubsczyk, B. ;
Kollars, M. ;
Traby, L. ;
Zwiauer, K. ;
Gleiss, A. ;
Quehenberger, P. ;
Kyrle, P. A. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (08) :707-713
[9]   Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres [J].
Escobar, M. ;
Maahs, J. ;
Hellman, E. ;
Donkin, J. ;
Forsyth, A. ;
Hroma, N. ;
Young, G. ;
Valentino, L. A. ;
Tachdjian, R. ;
Cooper, D. L. ;
Shapiro, A. D. .
HAEMOPHILIA, 2012, 18 (06) :971-981
[10]   Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven®] in elective orthopaedic surgery in haemophilic patients with inhibitors [J].
Giangrande, P. L. F. ;
Wilde, J. T. ;
Madan, B. ;
Ludlam, C. A. ;
Tuddenham, E. G. D. ;
Goddard, N. J. ;
Dolan, G. ;
Ingerslev, J. .
HAEMOPHILIA, 2009, 15 (02) :501-508